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516Prognostic Factors for Outcomes of Pediatric Patients
with Refractory or Relapsed Acute Leukemia
Undergoing Allogeneic Progenitor Cell Transplantation
Nobuhiro Watanabe,1 Yoshiyuki Takahashi,2 Kimikazu Matsumoto,1 Asahito Hama,2
Hideki Muramatsu,2 Sayoko Doisaki,2 Keizo Horibe,3 Koji Kato,1 Seiji Kojima2Allogeneic stem cell transplantation (SCT) is the only curative therapy for patients with refractory or re-
lapsed acute leukemia, although the prognosis remains poor. Few reports have described outcomes of
SCT in pediatric patients with refractory acute leukemia. To identify prognostic factors for these patients,
we retrospectively evaluated SCT outcomes for advanced acute leukemia in 82 pediatric patients from 3
transplant units in Nagoya City between 1990 and 2008. Median age at transplantation was 8 years (range,
0.5-17 years). Transplantation was performed in the first refractory relapse for 53 patients (64.6%), in the
second or subsequent relapse for 16 patients (19.5%), and during primary induction failure for 13 patients
(15.9%). Only 4 patients (4.9%) underwent transplantation in the untreated first relapse, and 39 patients
(47.6%) received unrelated donor progenitor cells. Of the 82 patients, 61 died (77.9%), with a median survival
of 7.1 months (95% confidence interval [CI], 4.2-10.0 months). Median disease-free survival (DFS) was 4.7
months (95% CI, 2.6-6.9 months). In multivariate analysis, peripheral blood blasts, cord blood transplanta-
tion, and more than 3 courses of previous salvage chemotherapy were predictive of DFS. These results sup-
port the notion that allogeneic SCT offers only a small chance of cure for most pediatric patients with
refractory or relapsed acute leukemia, and suggest that reduction of the leukemia burden and earlier optimal
timing of transplantation are essential for long-term survival even in patients with refractory acute leukemia.
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Although advances in chemotherapy have im-
proved the prognosis for patients with acute leukemia,
outcomes remain poor in patients with refractory or re-
lapsed disease [1-7]. Moreover, much of the literature
has reported results for pediatric and adult patients
together, making outcomes in pediatric patients alone
difficult to determine. The present study sought to
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acute leukemia who had not achieved remission with
chemotherapy.PATIENTS AND METHODS
Three transplant units in Nagoya City were asked
to provide data on all pediatric patients (aged#17 years
at the time of transplantation) who underwent alloge-
neic SCT for acute lymphoblastic leukemia (ALL;
n 5 48), acute myelogenous leukemia (AML; n 5 31),
or acute undifferentiated leukemia (AUL; n 5 3) after
failing to achieve remission between 1990 andOctober
2008. Remission was defined as morphologically nor-
mal bone marrow (BM) without cytogenetic evidence
of leukemia, and a morphologically normal peripheral
blood (PB) smear with recovery of PB hematologic
values, including a platelet count .100  109/L and
an absolute neutrophil count .1.5  109/L. Chromo-
somal abnormalities classified as good prognostic fea-
tures included AML with translocation 8;21 (n 5 3)
and ALL with hyperdiploid karyotype (n5 2). Karyo-
types considered to have a poor prognosis included
AML and ALL with abnormalities of chromosome 7
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11 (n 5 12), and translocation 1;19 (n 5 2), t4;11
(n 5 4), or t9;22 (n 5 10). The other 46 patients
(including 14 patients with normal karyotype) were
assigned to the intermediate-risk category.
The results of HLA testing performed using stan-
dard serologic methods for HLA-A, -B, -DR, and -DR
identity were confirmed by high-resolution molecular
typing. The conditioning regimens used for transplan-
tation and protocols for graft-versus-host disease
(GVHD) prophylaxis were those used at our institu-
tions during the period when the patients underwent
transplantation. Conditioning regimens were classi-
fied as total body irradiation (10-12 Gy, divided into
4 fractions)-based myeloablative (MA), high-dose che-
motherapy-based MA, or reduced-intensity (RIC) [8].
Patients and donors provided written informed con-
sent, and unrelated donor cells were procured under
the auspices of the Japanese Marrow Donor Program
following the applicable current guidelines.Statistical Analysis
Data were collected to allow study of the following
subgroups: age at SCT (#10 years vs$11 years), year of
transplantation (1990-2000 vs 2001-2008), disease
status (primary induction failure [PIF] vs first or later
refractory relapse, untreated relapse, or chemoresistant
relapse), type of leukemia (ALL vs AML/AUL), num-
ber of salvage treatment courses before transplantation
(#2 vs$3), cytogenetics (good vs other), conditioning
regimen (total body irradiation vs chemotherapy only,
MA vs RIC), donor source (BM/PB vs cord blood
[CB]; HLA disparity), duration of previous first com-
plete remission (CR1) (#1 year vs.1 year), high disease
burden (% BM blasts before SCT or presence of circu-
latingblasts), acuteGVHD(aGVHD;grade 0-I vs grade
II-IV), and chronicGVHD(cGVHD;none vs limited vs
extensive). HLA disparity was considered a trinary
variable for risk factor analysis. The HLA-higher mis-
matched group included patients undergoing transplan-
tation fromarelateddonorwith$2antigenmismatches,
unrelated CB donors with$2 antigen mismatches, and
unrelated BM donors with $1 antigen mismatches.
The HLA-middle mismatched group included related
donors with 1 antigen mismatch, CB donors with 1
antigen mismatch, and unrelated matched BM donors.
The HLA-less mismatched group included HLA-
matched related donors.
Unadjusted survival probabilities were estimated
using the Kaplan-Meier method. Comparisons of
unadjusted between-group survival rates were made
using the log-rank test. Univariate analyses were per-
formed for various pretransplantation and transplanta-
tion variables related to disease-free survival (DFS),
nonrelapse mortality (NRM), and relapse rate at 5
years posttransplantation. Cox proportional hazardsregression modeling was used to assess the ability of
patient characteristics and treatment-related variables
to predict survival. All variables showing a probable
association (P\.10) with DFS, NRM, or relapse rate
in univariate analyses were included in the Cox pro-
portional hazards model. Time-dependent covariates
were used to study aGVHD and cGVHD. All statisti-
cal tests were two-sided, and differences were consid-
ered statistically significant at P \.05. Associations
between discrete variables were assessed by Fisher’s
exact and generalized exact tests. All analyses were
performed using SPSS software (SPSS, Chicago, IL).
RESULTS
Patient Characteristics
Demographic data and disease characteristics are
shown inTable 1.Median patient age at transplantation
was 8 years (range, 0.5-17 years). Transplantation was
performed during the first refractory relapse in 53 pa-
tients (64.6%), during a second or subsequent relapse
in 16 patients (19.5%), and during PIF in 13 patients
(15.9%). Four patients (4.9%) underwent transplanta-
tion during an untreated first relapse, and the remaining
78 patients were unable to attain CR despite induction
chemotherapy. Fifty-four patients (65.8%)had received
$3 courses of salvage chemotherapy, and 49 patients
(59.7%) had experienced early relapse after a remission
lasting less than 1 year. For the 43 patients who re-
ceived an allograft from a related donor, 33 (40.2%)
were HLA-identical and 10 (12.2%) were HLA-
mismatched. Of the 39 unrelated donors, 20 (24.4%)
were HLA-identical and 19 (23.1%) were HLA-
mismatched. The transplant source was BM in 65 pa-
tients (79.3%), mobilized PB stem cells in 9 patients
(11.0%), and CB in 8 patients (9.8%). Three patients
(3.7%) received an RIC regimen, whereas 79 patients
(96.3%) received an MA conditioning regimen.
GVHD prophylaxis consisted primarily of tacrolimus
combination therapy (37 [45.1%]), cyclosporine com-
bination therapy (21 [25.6%]), or methotrexate alone
(21 [25.6%]).
Survival, NRM, and Relapse Rate
Sixty-one of the 82 patients died (77.9%), with
amedian survival of 7.1months (95% confidence inter-
val [CI], 4.2-10.0 months). A total of 66 patients
(83.4%) either died or displayed disease progression.
MedianDFSwas 4.7months (95%CI, 2.6-6.9months)
(Figure 1).Median follow-up for the disease-free survi-
vors was 8.6 years (range, 0.37-19 years). On univariate
analysis, significant prognostic factors for DFS were
stem cell type, presence of PB blasts before SCT,
more than 3 courses of previous salvage chemotherapy,
and cGVHD (Table 2).
NRM occurred in 25 patients (30.5%), including
9 from respiratory failure, including interstitial
Table 1. Patient Characteristics
n %
Number of patients 82
Sex
Male 52 63.4
Female 30 36.4
Diagnosis
ALL 48 58.5
AML 31 37.8
AUL 3 3.7
Age
Median (range), years 8 (0.5-17)
#10 years 55 67.1
$11 years 27 32.9
Year of transplantation
1990-2000 44 53.7
2001-2008 38 46.3
Disease status before SCT
Primary induction failure 13 15.9
First relapse refractory 53 64.6
>First relapse refractory 16 19.5
Number of chemotherapy cycles
before SCT
Untreated first relapse 4 4.9
1 cycles 8 9.8
2 cycles 16 19.5
$3 cycles 54 65.8
Cytogenetic subgroup
Good 5 6.1
Intermediate 44 53.7
Bad 30 36.6
Missing 2 2.4
Stem cell type
BM 65 79.3
PB 9 11
CB 8 9.8
Donor type
BM/PB
Matched related 33 40.2
Mismatched related 10 12.2
One locus mismatched 3 3.7
Two loci mismatched 7 8.5
Matched unrelated 20 24.4
Mismatched unrelated
One locus mismatched 11 13.4
CB 8 9.8
One locus mismatched 3 3.7
Two loci mismatched 5 6.1
Donor sex
Male 38 46.3
Female 44 53.7
Conditioning regimen
Reduced-intensity conditioning
Yes 3 3.7
No 79 96.3
Total body irradiation
Yes 76 92.7
No 6 7.3
Use of ATG 11 13.4
Use of busulfan 47 57.3
Use of cyclophosphamide 14 17.1
Use of melphalan 66 80.5
GVHD prophylaxis
MTX alone 21 25.6
Cyclosporine + MTX 19 23.2
Cyclosporine + MTX + PSL 1 1.2
Cyclosporine + PSL 1 1.2
Tacrolimus + MTX 36 43.9
Tacrolimus + MMF 1 1.2
None 3 3.7
Leukemia burden at SCT
Presence of circulating blasts
Yes 44 53.7
(Continued )
Table 1. (Continued )
n %
No 38 46.3
$25% marrow blasts
Yes 57 69.5
No 20 24.4
Missing 5 6.1
Duration of CR1, months
<6 33 40.2
6-12 16 19.5
$12 31 37.8
Missing 2 2.4
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; AUL, acute undifferentiated leukemia; SCT, stem cell trans-
plantation; BM, bone marrow; PB, peripheral blood; CB, cord blood;
ATG, antithymocyte globulin; MMF, mycophenolate mofetil; MTX, meth-
otrexate; PSL, prednisolone.
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litis obliterans; 6 from infection; 5 from severe aGVHD;
3 from multiorgan failure, including veno-occlusive
disease; and 2 from encephalopathy (Figure 2). On
univariate analysis, no risk factors were associated with
higher NRM rates.
A total of 41 patients (50%) relapsed, with amedian
relapse time from SCT of 10.7 months (95% CI,
3.2-18.1 months) (Figure 3). Risk factors associated
with relapse rate included stem cell type, presence of
PB blasts before SCT, the number of salvage chemo-
therapy, and cGVHD (Table 3). In contrast, age, sex,
diagnosis (ALL vs AML/AUL), cytogenetic subgroup,
and duration of CR1 were not significantly associated
with clinical outcomes.
Multivariate Analysis
Cox regression analysis showed that the number of
treatment courses before SCT, stem cell type, and the
presence of PB blasts before SCT were predictive of
DFS (Table 2). No prognostic factors for NRM were
identified, whereas the number of treatment courses
before SCT, stem cell type, and presence of PB blasts
were associated with relapse rate (Table 3). In patients
receiving a BM or PB graft, HLA disparity also was
associated with DFS and relapse rate (Tables 2 and 3).
Figure 4 shows the manner in which the predicted
DFS probability under the Cox regression model sum-
marized in Table 2 varies with PB blasts and number of
treatment courses before SCT. In the 54 patients
receiving $3 courses of treatment before transplanta-
tion, DFS at 5 years was 28.0% (range, 19.0%-
37.0%) in 25 patients without circulating PB blasts
and 3.4% (range, 0%-6.8%) in 29 patients with PB
blasts (P 5 .004).DISCUSSION
The recent development and implementation of
more aggressive chemotherapy protocols and better
Figure 1. Kaplan-Meier curve for DFS.
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led to improving survival rates in children with acute
leukemias, including lymphoid and myelogenous ma-
lignancies [9-14]. Nonetheless, current therapeuticTable 2. Prognostic Factors Associated with DFS
Variable 5-Year DFS, % Univari
All recipients
Year of transplantation
1990-2000 29.5 ± 6.9
2001-2008 13.2 ± 5.5
Number of previous therapies
#2 35.7 ± 9.1
$3 14.8 ± 4.8
Stem cell type
BM/PB 24.3 ± 5.0
CB 0
% BM blasts before SCT
<25% (n 5 20) 35.0 ± 10.7
$25% (n 5 57) 19.3 ± 5.2
PB blast before SCT
Blast-negative 36.8 ± 7.8 <
Blast-positive 9.1 ± 4.3
Chronic GVHD
None 20.3 ± 6.8
Limited/extensive 42.3 ± 9.7
BM/PB recipients
Year of transplantation
1990-2000 31.7 ± 7.3
2001-2008 15.2 ± 6.2
Number of previous therapies
#2 43.5 ± 10.3
$3 15.7 ± 5.7
PB blast before SCT
Blast-negative 38.9 ± 8.1
Blast-positive 10.5 ± 5.0
HLA disparity
Match 30.2 ± 6.3
Mismatch 9.5 ± 6.4
Chronic GVHD
None 21.9 ± 7.3
Limited/extensive 44.0 ± 9.9
DFS indicates disease-free survival; BM, bone marrow; PB, peripheral blood; C
disease.results remain unsatisfactory, particularly for patients
with primary refractory or relapsed disease despite
salvage chemotherapy. In patients with refractory or
relapsed acute leukemia treated with allogeneic SCT,
long-term survival is generally poor [1-7]. Previous
studies of outcomes of allogeneic SCT for advanced
acute leukemia have been limited by the small number
of patients and the inclusion of a range of disease
statuses, from remission to refractory or relapsed
disease. Most studies also have included both pediatric
and adult patients, and few have examined pediatric
patients with acute leukemia who never achieved CR
[4]. In the present study, we evaluated a large number
of pretreatment variables for effects on transplantation
outcomes in pediatric patients.We found that the num-
berof treatment courses beforeSCT, stemcell type, and
the presence of PB blasts before SCT were indepen-
dently associated with DFS in pediatric patients with
refractory or relapsed acute leukemia, as has been
reported for adult patients [4-6,15-18]. In our study,
two-thirds of patients had receivedmore than 3 courses
of chemotherapy, making this a heavily pretreatedMultivariate
ate P Value HR 95% CI P Value
.098
.024 1
3.62 1.62-8.08 .002
.015 1
5.69 1.35-24.03 .018
.097
.001 1
3.24 1.61-6.54 .001
.013
.091
.014 1
4.98 2.02-12.26 <.001
.004 1
2.53 1.19-5.41 .016
.013 1
2.38 1.05-5.35 .037
.014
B, cord blood; SCT, stem cell transplantation; GVHD, graft-versus-host
Figure 2. Time to NRM for 82 patients with refractory or relapsed
acute leukemia.
520 Biol Blood Marrow Transplant 17:516-523, 2011N. Watanabe et al.groupofpatients. Inmultivariate analysis, fewer courses
of pretransplantation chemotherapy was associated
with better DFS and relapse rate. Similar observations
have been reported previously [3,15]. As Schmid et al.
[15] reported, this difference is not attributable to
a higher NRM, as might be expected given the higher
cumulative organ toxicity in heavily pretreated patients.
These authors also reported that disease stage at the
time of transplantation did not differ between patients
pretreated with 2 or$3 courses of salvage chemother-
apy. These observations might offer clues to guide the
selection of chemoresistant leukemic cells during re-
peated reinduction attempts and possibly favor earlier
timing of allogeneic SCT once acute leukemia appears
to be refractory to chemotherapy. Prompt transplanta-
tion using HLA-mismatched/haploidentical blood and
BM grafts might be warranted for patients without
a suitable related matched donor [19]. Patients whoFigure 3. Time to relapse for 82 patients with refractory or relapsed
acute leukemia.do not achieve remission after multiple salvage thera-
pies with circulating PB blasts might not be good
candidates for SCT.
We hypothesized that the leukemic burden, as
measured by the PB blast count and BM leukemia infil-
trate, would be important prognostic factors for out-
come. The results of our univariate and multivariate
analyses suggest that PB blasts can be predictive of
DFS. Our analysis confirms an association between
high disease burden and poor survival, as reported
previously [16-18]. The high relapse rate after SCT
suggests that current high-dose chemoradiation
regimens are often inadequate to eradicate leukemia.
Multiple preparative regimens have been tested in the
phase II setting in an attempt to improve outcomes in
patients with advanced leukemia, but none has demon-
strated superiority over other regimens [20]. This find-
ing supports the current practice of attempting
cytoreduction before proceeding with transplantation
in patients showing circulating blasts or extensive BM
disease. This argues in favor of further attempts at blast
reduction in patients with high blast counts, inevitably
increasing the time to transplantation.
Andrew et al. [21] reported an association between
a graft-versus-leukemia (GVL) effect andGVHD after
allogeneic SCT for refractory or relapsed acute leuke-
mia. However, in our study, cGVHDwas significantly
associated with DFS and relapse rate in the univariate
analysis, but not in multivariate Cox regression model.
In the study of Andrew et al., the leukemic burden be-
fore transplantationwas not included as a pretransplan-
tation variable in the analysis of factors that had
a significantly effect on clinical outcomes. A European
report of a large number of patients receiving cyclo-
sporine andmethotrexate asGVHDprophylaxis docu-
mented a greater GVL effect associated with aGVHD
in CR1 compared with relapse [22]. High leukemic
burden and selection of chemoresistant leukemic cells
during repeated reinduction attempts may cause the
failure of complete donor chimerism, preventing the
development of cGVHD or a GVL effect in these
patients.
We found no difference in DFS, NRM, or relapse
rate between patients with ALL and those with AML/
AUL. A study based on data from the International
Bone Marrow Transplant Registry reported that the
GVL effect was greatest in AML, was of borderline sig-
nificance in chronic myelogenous leukemia, and was
absent in ALL [23]. However, these patients underwent
BM transplantation while in CR1. Ringden et al. [22]
noted that the GVL effect is most obvious in early dis-
ease. Our findings demonstrate that leukemic burden
is a more important factor in DFS than the difference
in disease between ALL and AML/AUL in patients
receiving SCT with refractory leukemia.
As in previous reports [16,21], we found a nonsig-
nificant trend in survival associated with classical
Table 3. Risk Factors Associated with Relapse Rate
Multivariate
Variables 5-Year Relapse Rate, % Univariate P Value HR 95% CI P Value
All recipients
Number of previous therapies
#2 59.6 ± 12.5 .076 1
$3 70.7 ± 7.4 3.01 1.29-7.03 .011
Stem cell type
BM/PB 67.7 ± 7.0 .034 1
CB 100 4.78 1.18-19.42 .029
PB blast before SCT
Blast-negative 53.4 ± 11.0 <.001 1
Blast-positive 88.2 ± 6.3 3.19 1.55-6.56 .002
Chronic GVHD
None 78.2 ± 7.4 .004
Limited/extensive 53.0 ± 12.6
BM/PB recipients
Number of previous therapies
#2 53.6 ± 13.9 .059 1
$3 75.7 ± 7.3 3.66 1.51-8.83 .004
PB blast before SCT
Blast-negative 51.9 ± 11.2 .002 1
Blast-positive 86.8 ± 7.0 2.33 1.05-5.16 .038
HLA disparity
Match 61.5 ± 8.3 .041 1
Mismatch 83.2 ± 10.5 2.51 1.09-5.77 .031
Chronic GVHD
None 76.0 ± 8.1 .009
Limited/extensive 53.1 ± 12.6
BM indicates bone marrow; PB, peripheral blood; CB, cord blood; SCT, stem cell transplantation; GVHD, graft-versus-host disease.
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reported a low relapse rate and better long-term survival
after SCT in patients with inv16 and t15;17, even in non-
complete remission [24,25]. In our study, there were no
patients with inv16 and t15;17, and few patients with
a good-risk chromosomal abnormality.Given the limited
number of patients with good-risk abnormalities, theFigure 4. Effect of previous therapy and the presence of PB blasts pre-
transplantation on DFS at 5 years. Outcomes for 54 patients who re-
ceived $3 courses of therapy before transplantation are shown. DFS
at 5 years was 28.0% (range, 19.0%-37.0%) in 25 patients without circu-
lating PB blasts (solid line) and 3.4% (range, 0%-6.8%) in 34 patients with
PB blasts (dashed line) (P 5 .004).actual significance of each additional abnormality should
be investigated in a larger number of patients.
In our study, CB transplantation was significantly
associated with DFS and relapse rate. The diminished
GVHD after CB transplantation reported by some
investigators raises the concern that CB-derived cells
might not be capable of generating a sufficientGVL re-
sponse. However, the incidence of recurrent leukemia
after CB transplantation does not differ from that
reported in BM or PB transplantation [26]. Because
of the limited number of patients in our subgroup
analyses and the possibility of an unidentified bias
in stem cell source selection, our findings should be
verified by further analysis in a larger population.
In our BM and PB recipients, HLA disparity was
significantly associated with DFS and relapse. This
finding suggests that there may be several reasons for
the increased risk of relapse in the HLA-mismatched
group, such as selection bias and more heavy immuno-
suppressive therapy. Increased immunosuppression
might decrease the GVL effect [27].
Despite all of the recent advances in SCT, survival
of children with refractory or relapsed acute leukemia
has not changed significantly since the first reports of
BM transplantation more than 3 decades ago [28].
Our results suggest that innovative strategies are justi-
fied if allografting is to be contemplated in most pedi-
atric patients with refractory acute leukemia. Recent
sequential use of intensive chemotherapy, RIC
transplantation, and prophylactic donor lymphocyte
522 Biol Blood Marrow Transplant 17:516-523, 2011N. Watanabe et al.transfusions might represent steps forward in the
treatment of refractory myelogenous malignancies
[15,29].
Realistically, increasing survival to any significant
degree in pediatric patients with refractory acute leuke-
mia will require novel approaches to overcoming the
intrinsic resistance of leukemia cells to high-dose che-
moradiotherapy. The risk factors for mortality and
relapse identified in the present study may help guide
clinicians in making recommendations for allogeneic
SCT in pediatric patients with refractory acute leuke-
mia. Our data suggest that earlier optimal timing of
transplantation will be associated with better clinical
outcomes in patients with refractory or relapsed acute
leukemia, regardless of other factors. Conversely,
transplantation might not be indicated for patients
with persistent PB blasts after 3 courses of salvage
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